MedMesh.i
Checkpoint
PubMed
Racine
Checkpoint
PubMed
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Checkpoint (PubMed)

Index « MedMesh.i » - entrée « Recombinant Fusion Proteins »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Receptors, Tumor Necrosis Factor, Type II < Recombinant Fusion Proteins < Recombinant Proteins  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 14.
Ident.Authors (with country if any)Title
000393 (2019) Florian Kleinegger [Autriche] ; Eva Hofer [Autriche] ; Christina Wodlej [Autriche] ; Nicole Golob-Schwarzl [Autriche] ; Anna Maria Birkl-Toeglhofer [Autriche] ; Alexander Stallinger [Autriche] ; Johannes Petzold [Autriche] ; Anna Orlova [Autriche] ; Stefanie Krassnig [Autriche] ; Robert Reihs [Autriche] ; Tobias Niedrist [Autriche] ; Harald Mangge [Autriche] ; Young Nyun Park [Corée du Sud] ; Michael Thalhammer [Autriche] ; Ariane Aigelsreiter [Autriche] ; Sigurd Lax [Autriche] ; Christoph Garbers [Allemagne] ; Peter Fickert [Autriche] ; Stefan Rose-John [Allemagne] ; Richard Moriggl [Autriche] ; Beate Rinner [Autriche] ; Johannes Haybaeck [Allemagne]Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival.
000A80 (2017) Laurie S. Davis ; Andreas M. ReimoldResearch and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.
000A90 (2017) Janos L. Tanyi [États-Unis] ; Caitlin Stashwick ; Gabriela Plesa ; Mark A. Morgan ; David Porter ; Marcela V. Maus ; Carl H. JunePossible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells.
000B86 (2017) Julie C. Fitzgerald [États-Unis] ; Scott L. Weiss ; Shannon L. Maude ; David M. Barrett ; Simon F. Lacey ; J Joseph Melenhorst ; Pamela Shaw ; Robert A. Berg ; Carl H. June ; David L. Porter ; Noelle V. Frey ; Stephan A. Grupp ; David T. TeacheyCytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
000C32 (2017) Chen Tian [République populaire de Chine] ; Hongliang Yang [République populaire de Chine] ; Lei Zhu [République populaire de Chine] ; Qing Zhang [République populaire de Chine] ; Zeng Cao [République populaire de Chine] ; Yizhuo Zhang [République populaire de Chine]Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement.
000E15 (2016) Alexei A. Grom [États-Unis] ; Annacarin Horne [Suède] ; Fabrizio De Benedetti [Italie]Macrophage activation syndrome in the era of biologic therapy.
000E64 (2016) Simon Tarp [Danemark] ; Gil Amarilyo [Israël] ; Ivan Foeldvari ; Robin Christensen [Danemark] ; Jennifer M P. Woo [États-Unis] ; Neta Cohen [Israël] ; Tracy D. Pope [États-Unis] ; Daniel E. Furst [États-Unis]Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials.
001096 (2015) Freya A. Goumas [Allemagne] ; Reinhild Holmer [Allemagne] ; Jan-Hendrik Egberts [Allemagne] ; Artur Gontarewicz [Allemagne] ; Carola Heneweer [Allemagne] ; Ulf Geisen [Allemagne] ; Charlotte Hauser [Allemagne] ; Maria-Margarete Mende [Allemagne] ; Karen Legler [Allemagne] ; Christoph Röcken [Allemagne] ; Thomas Becker [Allemagne] ; Georg H. Waetzig [Allemagne] ; Stefan Rose-John [Allemagne] ; Holger Kalthoff [Allemagne]Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer.
001153 (2015) Normi Bruck [Allemagne] ; Anja Schnabel [Allemagne] ; Christian M. Hedrich [Allemagne]Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches.
001461 (2013) Matthew L. Stoll [États-Unis] ; Randy Q. CronTreatment of juvenile idiopathic arthritis in the biologic age.
001762 (2012) Anne V. Miller [États-Unis] ; Sriya K M. RanatungaImmunotherapies in rheumatologic disorders.
001785 (2012) Peter J. Bugelski [États-Unis] ; Pauline L. MartinConcordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets.
001977 (2010) Misato Hashizume [Japon] ; Yasushi Uchiyama ; Naoto Horai ; Naohisa Tomosugi ; Masahiko MiharaTocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production.
001B41 (2008) Yasuo Adachi [Japon] ; Naoko Yoshio-Hoshino ; Norihiro NishimotoThe blockade of IL-6 signaling in rational drug design.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/MedMesh.i -k "Recombinant Fusion Proteins" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/MedMesh.i  \
                -Sk "Recombinant Fusion Proteins" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    indexItem
   |index=    MedMesh.i
   |clé=    Recombinant Fusion Proteins
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021